###begin article-title 0
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 175 183 <span type="species:ncbi:9606">Patients</span>
Utility of Pretreatment Bilirubin Level and UGT1A1 Polymorphisms in Multivariate Predictive Models of Neutropenia Associated with Irinotecan Treatment in Previously Untreated Patients with Colorectal Cancer
###end article-title 0
###begin title 1
Purpose
###end title 1
###begin p 2
###xml 79 85 79 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
Statistical models for predicting hematologic toxicity were evaluated based on UGT1A1 polymorphisms and baseline serum bilirubin.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 295 296 295 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 404 410 404 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Blood DNA samples were collected from 113 patients with untreated metastatic colorectal cancer receiving irinotecan (FOLFIRI, n = 36; mIFL, n = 41; CapeIRI, n = 36). The primary endpoint was absolute neutrophil count nadir during first treatment cycle. Linear regression models, with increased R2 implying important additional predictive power, sequentially added age, sex, baseline bilirubin level, and UGT1A1 genotype.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 29 30 29 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 301 302 277 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 313 321 <span type="species:ncbi:9606">Patients</span>
All models demonstrated low R2, suggesting unaccounted variables. UGT1A1 genotype added approximately8-9% during cycle 1 and from approximately7% [mIFL regimen] to 26% [CapeIRI regimen] after cycle 1. Correlation between genotype and overall ANC nadir without regard to treatment was low (R = -0.201, P = 0.035). Patients with genotype 7/7 may have increased risk for severe neutropenia, but data are insufficient to characterize this. Contribution of baseline bilirubin level was negligible.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
Ability of UGT1A1 or baseline bilirubin to predict neutropenia is low and depends on regimen.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 130 133 130 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">[1]</xref>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">[2</xref>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">8]</xref>
###xml 114 121 <span type="species:ncbi:9606">patient</span>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
Chemotherapy in conjunction with selected targeted agents has largely been responsible for steady improvements in patient survival[1], and, in patients with metastatic disease, treatment with combinations of the most active cytotoxic agents yields median overall survival in excess of 20 months[2-8]. The attainment of palliative benefit may be thwarted, however, by the unwelcome development of treatment-emergent toxicity associated with chemotherapy, which may require dose modification, interruption of therapy, or treatment discontinuation.
###end p 10
###begin p 11
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">[9</xref>
###xml 320 323 320 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">13]</xref>
###xml 623 631 <span type="species:ncbi:9606">patients</span>
###xml 692 699 <span type="species:ncbi:9606">patient</span>
Techniques to prospectively identify individuals who may be at risk for development of treatment-related toxicity include clinical risk scores, assays for biologic substances with possible predictive value, and, increasingly, pharmacogenetic testing for specific polymorphisms that inform host interactions with drugs[9-13]. The toxicity of chemotherapy, as well as its efficacy, may in part be due to heritable genetic factors modulating drug activation, metabolism, clearance, and excretion that play a role in cellular and tissue responses to treatment. Predictive genetic markers could therefore be useful in selecting patients most likely to benefit from therapy or to determine optimal patient-specific treatment regimens.
###end p 11
###begin p 12
###xml 297 301 297 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">[14]</xref>
###xml 341 349 341 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1</xref>
###xml 499 502 499 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">[15</xref>
###xml 503 506 503 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16]</xref>
###xml 508 514 508 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 649 652 649 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">[17</xref>
###xml 653 656 653 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19]</xref>
###xml 724 730 724 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 919 928 919 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1*28</italic>
###xml 1209 1212 1209 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">[20</xref>
###xml 1213 1216 1213 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24]</xref>
###xml 60 68 <span type="species:ncbi:9606">patients</span>
The marked interpatient variability in toxicity reported in patients with metastatic colorectal cancer (mCRC) receiving combination therapy with irinotecan, leucovorin, and 5-fluorouracil infusion (FOLFIRI) has been attributed to differences in levels of SN-38, the active metabolite of irinotecan[14]. The complex metabolism of irinotecan (Figure 1) includes inactivation of SN-38 by glucuronidation, a sequence of events mediated by the enzyme uridine diphosphate glucuronosyltransferase (UGT) 1A1[15,16]. UGT1A1 also catalyzes the glucuronidation of bilirubin; reduced expression of UGT has been associated with disorders of bilirubin homeostasis[17-19]. Of great interest is a polymorphism in the promoter region of the UGT1A1 gene where a variable number of repeating TA units is observed in the general population. A 6-repeat allele is the most commonly identified (wild type) form; a 7-repeat allele (designated UGT1A1*28) is associated with dramatically reduced expression of the inactivating enzyme and thus with prolonged persistence of active SN-38. The impaired ability to inactivate SN-38 in some individuals may lead to an increased risk of irinotecan-related toxicity, specifically, neutropenia[20-24].
###end p 12
###begin p 13
###xml 199 205 199 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 215 221 215 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 356 367 356 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Semin Oncol</italic>
Major pathways of irinotecan metabolism and disposition. A reaction catalyzed by carboxylesterase-2 yields SN-38, the active metabolite. Glucuronidation of SN-38 to SN-38G is catalyzed by the enzyme UGT1A1. Several UGT1A1 polymorphisms exist, coding for a spectrum of enzyme expression and varying ability to metabolize SN-38. This figure was published in Semin Oncol, 32, Tan BR, McLeod HL, Pharmacogenetic influences on treatment response and toxicity in colorectal cancer, 113-9, Copyright Elsevier (2005).
###end p 13
###begin p 14
###xml 6 12 6 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 223 229 223 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 288 294 288 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 409 413 409 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">[21]</xref>
###xml 562 568 562 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 195 203 <span type="species:ncbi:9606">patients</span>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
###xml 584 592 <span type="species:ncbi:9606">patients</span>
Since UGT1A1 plays a central role in the chemical modification of both bilirubin and the active metabolite of irinotecan, it has been suggested that pretreatment serum bilirubin levels in cancer patients reflect underlying UGT1A1 polymorphisms and thus serum bilirubin may substitute for UGT1A1 genotyping to risk-stratify patients for the occurrence of irinotecan-related toxicity (e.g., severe neutropenia) [21]. In this study, we assessed the contribution of baseline bilirubin level to statistical models for predicting neutropenia based on age, gender, and UGT1A1 genotype among patients receiving first-line irinotecan-based chemotherapy for mCRC.
###end p 14
###begin title 15
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and Methods
###end title 15
###begin title 16
Study Design
###end title 16
###begin p 17
###xml 344 348 344 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">[25]</xref>
###xml 444 448 444 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">[26]</xref>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
###xml 327 335 <span type="species:ncbi:9606">patients</span>
###xml 454 462 <span type="species:ncbi:9606">patients</span>
This study was conducted as a companion study to two clinical trials evaluating irinotecan in combination with other agents in patients with mCRC. These trials included a phase III, multicenter, randomized investigation of the efficacy and safety of three irinotecan regimens (FOLFIRI, mIFL, and CapeIRI) in chemotherapy-naive patients (BICC-C)[25] and a two-arm phase II study of irinotecan and 5-FU/LV administered with or without thalidomide[26]. All patients from whom samples were obtained for pharmacogenetic analysis signed a separate informed consent for participation in the companion study. The final protocol, any amendments, and informed consent documentation were reviewed and approved by the institutional review boards and/or Independent Ethics Committees at each of the centers participating in the study.
###end p 17
###begin p 18
###xml 96 97 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 110 111 110 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 132 133 132 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 165 166 165 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 225 226 225 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 238 239 238 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 264 265 264 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 364 365 364 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 402 403 402 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
###xml 461 469 <span type="species:ncbi:9606">Patients</span>
###xml 572 580 <span type="species:ncbi:9606">Patients</span>
###xml 734 742 <span type="species:ncbi:9606">patients</span>
Participants in the BICC-C trial (N = 430) were randomly assigned to receive irinotecan 180 mg/m2, LV 400 mg/m2, 5-FU bolus 400 mg/m2, and infusional 5-FU 2,400 mg/m2 over 46 hours every 2 weeks (FOLFIRI); irinotecan 125 mg/m2, LV 20 mg/m2, and bolus 5-FU 500 mg/m2 weekly for 2 weeks followed by a week of no chemotherapy (modified [m]IFL); or irinotecan 250 mg/m2 on day 1 and capecitabine 1,000 mg/m2 orally twice daily for 14 days, every 3 weeks (CapeIRI). Patients underwent an additional randomization to concurrent celecoxib (400 mg orally twice daily) or placebo. Patients in the phase II study were randomly assigned to receive mIFL (as per the regimen in BICC-C) (N = 40) with or without thalidomide in a 3-week cycle. Only patients who did not receive thalidomide were included in this analysis. Of 113 samples analyzed, 107 were from the BICC-C trial and 6 were from the phase II trial.
###end p 18
###begin p 19
###xml 6 18 <span type="species:ncbi:9606">participants</span>
Study participants provided separate written informed consent for genetic testing, in addition to consent obtained at entry into treatment protocols. Participation in this study was voluntary and had no bearing on participation in treatment protocols.
###end p 19
###begin title 20
Testing of Clinical Specimens
###end title 20
###begin p 21
###xml 173 179 161 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 322 326 310 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">[27]</xref>
###xml 50 57 <span type="species:ncbi:9606">patient</span>
Blood was obtained (approximately20 mL) from each patient for DNA extraction. All DNA extraction and genotyping was performed at a central laboratory. Identification of the UGT1A1 promoter and determination of the number of TA repeats was performed using a high-throughput genotyping assay as described in detail elsewhere[27]. The promoter sequence with TA repeats is referred to as TA indel (insertion/deletion). Only individuals with genotypes 6/6, 6/7, and 7/7 were included in this analysis. Blood samples for bilirubin measurement were collected at participating sites during clinic visits as specified by trial protocols. Serum bilirubin and hematologic indices were assessed using standard laboratory methods.
###end p 21
###begin title 22
Statistical Methods
###end title 22
###begin p 23
###xml 570 576 570 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 833 841 <span type="species:ncbi:9606">patients</span>
The analysis data set consisted of all patients with an evaluable DNA sample who received at least one dose of irinotecan. The primary outcome measurement was nadir in absolute neutrophil count (ANC) and most severe neutropenia grade during the first treatment cycle for each regimen (mIFL, FOLFIRI, and CapeIRI), with grade 3 neutropenia defined as ANC nadir below 1,000; grade 4, as ANC nadir below 500. Secondary safety endpoints were ANC nadir and most severe neutropenia grade after the first treatment cycle and during the entire treatment period. Covariates were UGT1A1 genotype, baseline bilirubin level (continuous variable), age (continuous variable), and gender. Statistical analysis modeled the relative contributions of covariates on ANC nadir associated with a specific treatment. Due to the relatively small number of patients analyzed for each treatment, and the resulting wide confidence intervals, it was difficult to demonstrate sufficient homogeneity of the effects across treatments to allow for a pooled analysis. Therefore, a pooled analysis is not presented.
###end p 23
###begin p 24
###xml 423 424 423 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 554 555 554 555 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 711 712 711 712 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 847 848 847 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 939 940 939 940 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1104 1105 1104 1105 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Allele and genotypic frequencies were calculated and tested for association using chi-square tests. Linear regression was used to assess the relative predictive power of the covariates for ANC nadir. Models were generated that adjusted for age and gender (model 1); age, gender, and baseline bilirubin level (model 2); age, gender, and genotype (model 3); and all 4 covariates (model 4). Partial correlation coefficients (R2) were used to partition variability in the primary outcome measure into relative components attributable to each covariate. The R2 for a model reflects the proportion of variation in response that is explained by factors included in the model. When comparing models, the difference in R2 provides the additional proportion of response variation that is explained by adding factors to the model; a substantial increase in R2 implies that the added factor contributes predictive power. Confidence intervals for the R2 values associated with each model were calculated with a resampling bootstrap method; if the lower limit exceeded 0 in conjunction with a substantial increase in R2, the additional factors in the model were considered to carry statistically significant predictive power.
###end p 24
###begin title 25
Results
###end title 25
###begin title 26
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient Characteristics, UGT1A1 Genotypes, and Treatment Tolerance
###end title 26
###begin p 27
###xml 281 287 281 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 385 392 385 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 584 591 584 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl2">Table 2</xref>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 109 117 <span type="species:ncbi:9606">patients</span>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
###xml 451 458 <span type="species:ncbi:9606">patient</span>
###xml 466 474 <span type="species:ncbi:9606">patients</span>
Blood DNA was available for 113 patients, representing 107 of 430 patients from the BICC-C study and 6 of 40 patients from the phase II study of mIFL with or without thalidomide. Of these 113 patients, 36 received FOLFIRI, 41 received mIFL, and 36 received CapeIRI. Frequencies of UGT1A1 genotypes were approximately 44% for 6/6, 44% for 6/7, and 10% for 7/7 in the entire population (Table 1). TA indel genotypes 5/7, 5/8, and 7/8 each appeared in 1 patient. These patients were not included in the analysis. Sex, age, and performance status were comparable across treatment groups (Table 2). Median treatment exposures were 28.1 weeks (range, 2.1-105.9 weeks), 30.1 weeks (range, 1.1-95.1 weeks), and 18.1 weeks (range, 3.1-77.1 weeks) in FOLFIRI, mIFL, and CapeIRI groups, respectively.
###end p 27
###begin p 28
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
UGT1A1 genotype of evaluable population
###end p 28
###begin p 29
###xml 23 30 <span type="species:ncbi:9606">patient</span>
###xml 70 77 <span type="species:ncbi:9606">patient</span>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
Other represents a 5/7 patient in the FOLFIRI arm and a 6/8 and a 7/8 patient in the CapeIRI arm. These patients were not included in the model.
###end p 29
###begin p 30
Demographic characteristics of evaluable population
###end p 30
###begin p 31
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SD</italic>
###xml 25 32 25 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGOG PS</italic>
SD = standard deviation; EGOG PS = Eastern Cooperative Oncology Group performance status.
###end p 31
###begin p 32
###xml 445 451 445 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 492 499 492 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl3">Table 3</xref>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 109 117 <span type="species:ncbi:9606">patients</span>
###xml 145 153 <span type="species:ncbi:9606">patients</span>
###xml 182 190 <span type="species:ncbi:9606">patients</span>
###xml 266 273 <span type="species:ncbi:9606">patient</span>
Grade 4 neutropenia was experienced by patients across all treatment arms over the length of the study (2/36 patients administered FOLFIRI, 5/41 patients administered mIFL, and 4/36 patients receiving CapeIRI). First-cycle grade 4 neutropenia was experienced by one patient receiving FOLFIRI, four receiving mIFL, and three receiving CapeIRI. The most severe neutropenia grade during cycle 1, after cycle 1, and over all cycles is summarized by UGT1A1 TA indel genotype and chemotherapy arm (Table 3).
###end p 32
###begin p 33
Incidence of neutropenia during cycle 1, after cycle 1, and over all cycles, by grade, genotype, and chemotherapy arm
###end p 33
###begin title 34
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
Relationship of UGT1A1 Genotype to Baseline Bilirubin Level and Toxicity
###end title 34
###begin p 35
###xml 0 8 0 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Figure 2</xref>
###xml 45 51 45 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 160 166 160 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 976 977 976 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 345 353 <span type="species:ncbi:9606">patients</span>
###xml 545 553 <span type="species:ncbi:9606">patients</span>
###xml 664 672 <span type="species:ncbi:9606">patients</span>
Figure 2 shows baseline bilirubin levels and UGT1A1 TA indel genotype by treatment group, baseline bilirubin and ANC nadir by treatment group, and ANC nadir by UGT1A1 TA indel genotype and treatment group. Pretreatment bilirubin levels and ANC nadir did not correlate with genotype. Grade 4 toxicity occurred infrequently but was recorded among patients in all treatment groups, across all genotypes, and in all instances at normal levels of total bilirubin. Neutropenia grades 1-4 was found in every treatment group, and all grades occurred in patients with levels of total bilirubin in the normal range; high-grade hematologic toxicity most commonly occurred in patients with bilirubin levels of 1.0 mg/dL or less. The correlation between baseline bilirubin and overall ANC nadir without regard to treatment was low (R = -0.055); the correlation between genotype (number of copies of the 7 allele) and overall ANC nadir without regard to treatment was also low (R = -0.201, P = 0.035).
###end p 35
###begin p 36
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 53 55 53 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A,</italic>
###xml 106 109 106 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ANC</italic>
###xml 118 120 118 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B,</italic>
###xml 134 140 134 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 157 159 157 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C,</italic>
###xml 179 187 <span type="species:ncbi:9606">patients</span>
Baseline bilirubin levels and UGT1A1 indel genotype. A, baseline bilirubin and absolute neutrophil count (ANC) nadir. B, ANC nadir by UGT1A1 indel genotype. C, treatment group in patients receiving irinotecan.
###end p 36
###begin p 37
###xml 306 313 306 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl3">Table 3</xref>
###xml 726 729 726 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">[14</xref>
###xml 730 732 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 733 735 733 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 736 739 736 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29]</xref>
###xml 5 13 <span type="species:ncbi:9606">patients</span>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
###xml 362 370 <span type="species:ncbi:9606">patients</span>
###xml 745 752 <span type="species:ncbi:9606">patient</span>
###xml 848 856 <span type="species:ncbi:9606">Patients</span>
###xml 941 949 <span type="species:ncbi:9606">patients</span>
###xml 972 980 <span type="species:ncbi:9606">patients</span>
When patients were examined according to specific chemotherapy regimen, occurrences of grade 3 or 4 neutropenia were noted in small numbers of patients in all treatment groups, most commonly among patients receiving mIFL, among whom it was relatively evenly distributed across 6/6, 6/7, and 7/7 genotypes (Table 3). There was evidence of a trend indicating that patients with the 7/7 genotype have an increased risk for grade 4 neutropenia, but there were insufficient data to characterize this risk by regimen, and the heterogeneity between regimens does not justify pooling of the data for further analysis. The observed trend is similar to the association between grade 4 neutropenia and the 7/7 genotype observed by others[14,21,28,29]. One patient receiving FOLFIRI experienced first-cycle grade 3 and two had first-cycle grade 4 neutropenia. Patients receiving mIFL accounted for the most episodes of grade 3 or 4 neutropenia (3 and 4 patients, respectively). Among patients receiving CapeIRI, two had grade 3 and three had grade 4 neutropenia. There was no apparent relationship between baseline bilirubin levels and log (ANC) during first-cycle treatment or at any subsequent point during the study.
###end p 37
###begin p 38
###xml 31 37 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 76 83 76 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl4">Table 4</xref>
###xml 359 360 359 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
All prediction models based on UGT1A1 TA indel genotypes had low R2 values (Table 4), indicating that the percentage of total variation in ANC nadir attributable to these factors was inadequate to account for the observed effects and suggesting, therefore, the presence of additional, unidentified explanatory variables. Calculated values for the additional R2 for adding genotype to the full model were small, ranging from 3.4% (95% confidence interval [CI], 0.0-15.4%) to 26.0% (95% CI, 6.0-51.6%).
###end p 38
###begin p 39
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
Additional utility of UGT1A1 TA indel genotype in predictive models for first-cycle and all cycles ANC nadir containing covariates of age, sex, and total bilirubin level
###end p 39
###begin p 40
Full Model: ANC nadir = age + sex + baseline bilirubin + genotype. Reduced (Bilirubin) Model: ANC nadir = age + sex + baseline bilirubin.
###end p 40
###begin p 41
###xml 108 109 108 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 147 148 147 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Demog Model: ANC nadir = age + sex. Reduced (Genotype) Model: ANC nadir = age + sex + genotype. Additional R2 for adding genotype = difference in R2 between the full model and the reduced (bilirubin) model.
###end p 41
###begin p 42
Note: In the models above, ANC nadir, baseline bilirubin, and age were treated as continuous variables, and sex and genotype were treated as categorical variables.
###end p 42
###begin p 43
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ANC</italic>
###xml 34 35 34 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 33 35 33 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R<sup>2</sup></italic>
###xml 113 115 113 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CI</italic>
ANC = absolute neutrophil count; R2 = percent of total variation in ANC nadir explained by factors in the model; CI = confidence interval.
###end p 43
###begin p 44
###xml 158 159 158 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 258 259 258 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 303 309 303 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 591 598 591 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl4">Table 4</xref>
Age and gender, the major demographic variables, were poorly predictive of first-cycle ANC nadir for all chemotherapy regimens, especially FOLFIRI and mIFL (R2 = 1.9% [95% CI, 0.0-3.6%] and 5.0% [95% CI, 0.0-9.8%], respectively) in comparison with CapeIRI (R2 = 24.4% [95% CI, 5.5%-36.9%]). Addition of UGT1A1 genotype to the age and gender model increased the predictive value for first-cycle ANC nadir by a comparable small amount across all treatment groups (7.9-8.2%) as well as in the combined data set (7.4%), but these slight increases were associated with wide confidence intervals (Table 4, demog and reduced genotype models).
###end p 44
###begin p 45
###xml 110 116 110 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 210 211 210 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 324 331 324 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl4">Table 4</xref>
Baseline bilirubin was largely devoid of power to predict first-cycle ANC nadir in any model, with or without UGT1A1 genotype. Adding baseline bilirubin alone to the demographic model increased the predictive R2 value negligibly for all treatment regimens (0-0.1%) and had no predictive utility in the pooled data set (0%) (Table 4, models 1 and 3).
###end p 45
###begin p 46
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 123 124 123 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 364 370 364 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 730 737 730 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl4">Table 4</xref>
There was a trend toward a model containing UGT1A1 TA indel genotype, age, sex, and baseline bilirubin conferring greater R2 values for first-cycle ANC nadir (range, 9.8 [95% CI, 0.2-20.7%] to 32.6% [95% CI, 9.4-46.4%]) than predictive models containing age, sex, and baseline bilirubin (range, 1.7 [95% CI, 0.1-3.3] to 24.5% [95% CI, 2.5-36.7%]), suggesting that UGT1A1 TA indel genotype may offer an additional contribution to the prediction of ANC nadir beyond baseline bilirubin level. As with other statistical findings, confidence intervals were wide. This trend was consistent across all three chemotherapy arms for first-cycle ANC nadir and was also present in calculations for ANC nadir after cycle 1 and for all cycles (Table 4). Over all cycles, the contribution of the TA indel genotype was smallest for the FOLFIRI group (3.4%, [95% CI, 0.0-15.4%]) when compared with mIFL (14.6%, [95% CI, 0.4-37.2%]) and CapeIRI (17.1% [95% CI, 4.8-49.2%]).
###end p 46
###begin title 47
Discussion
###end title 47
###begin p 48
###xml 563 567 563 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">[30]</xref>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
###xml 346 353 <span type="species:ncbi:9606">patient</span>
###xml 397 405 <span type="species:ncbi:9606">patients</span>
Although new chemotherapy regimens have increased survival benefits in patients with colorectal cancer, toxicity leading to dose reduction and treatment discontinuation remains an obstacle to the full realization of such benefits. Thus, there is an incentive to optimize chemotherapy regimens based on the genetic profile of an individual cancer patient. Screening before chemotherapy to identify patients at risk of experiencing serious toxicities may be useful when selecting treatment regimens, adjusting dosages, or, in some cases, rejecting ineffective drugs[30].
###end p 48
###begin p 49
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 113 116 113 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">[14</xref>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
###xml 129 132 129 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35]</xref>
###xml 292 298 292 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 335 339 335 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">[29]</xref>
###xml 372 378 372 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 568 569 568 569 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 583 586 583 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">[20</xref>
###xml 587 589 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 590 593 590 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">36]</xref>
###xml 773 779 773 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 270 278 <span type="species:ncbi:9606">patients</span>
###xml 501 509 <span type="species:ncbi:9606">patients</span>
###xml 804 812 <span type="species:ncbi:9606">patients</span>
Several studies have demonstrated that UGT1A1 polymorphisms are associated with an increased risk for neutropenia[14,20,21,28,31-35]. A recent review of data from 10 pharmacogenetic studies of irinotecan suggests that risk for irinotecan-induced hematologic toxicity in patients positive for UGT1A1 7/7 is a function of irinotecan dose[29]. The power of models containing UGT1A1 polymorphisms, baseline bilirubin, and SN-38 AUC to predict ANC nadir has been evaluated previously in heavily pretreated patients receiving doses of irinotecan ranging from 300 to 350 mg/m2 every 3 weeks[20,21,36]. The objective of the current study was to evaluate the predictive power of statistical models that include baseline serum bilirubin level and single nucleotide polymorphisms for UGT1A1 to predict ANC nadir in patients with mCRC receiving irinotecan in the first-line setting.
###end p 49
###begin p 50
###xml 284 290 284 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 449 455 449 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 694 700 694 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 265 273 <span type="species:ncbi:9606">patients</span>
There were 113 patients in the evaluable population treated with one of three different irinotecan-based first-line therapies. Although this population was small, the numbers were sufficient for exploratory analyses within the broad confidence intervals. Among all patients combined, UGT1A1 genotype significantly predicted the rate of grade 4 neutropenia. Moreover, for each irinotecan-based chemotherapy regimen, there was a trend suggesting that UGT1A1 genotype contributes modestly to the prediction of ANC nadir during irinotecan treatment. This effect was similar across all treatment groups, although confidence intervals for the relationship were wide. The additional utility of adding UGT1A1 genotype based on the TA indel was approximately8-9% during the first treatment cycle for all regimens, ranged from 7-26% after the first treatment cycle, and was between 3% and 17% across all cycles. These findings suggest a modest role, at best, for pharmacogenomic profiling in irinotecan-based therapy.
###end p 50
###begin p 51
###xml 181 187 181 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 655 658 655 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">[20</xref>
###xml 659 661 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 662 665 662 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">36]</xref>
###xml 959 960 959 960 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1176 1182 1176 1182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 1263 1264 1263 1264 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1264 1267 1264 1267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">[21</xref>
###xml 1268 1271 1268 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">36]</xref>
###xml 1321 1327 1321 1327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 542 550 <span type="species:ncbi:9606">patients</span>
###xml 699 707 <span type="species:ncbi:9606">patients</span>
###xml 840 848 <span type="species:ncbi:9606">patients</span>
###xml 874 882 <span type="species:ncbi:9606">Patients</span>
Also, in the current study, baseline bilirubin levels were not correlated with ANC nadir, and the addition of baseline bilirubin to the predictive model incorporating age, sex, and UGT1A1 genotype failed to improve the explanatory power of the model for ANC nadir. These results suggest that there is no clinically useful relationship between bilirubin level and irinotecan hematologic toxicity in chemotherapy-naive adults with mCRC treated with standard irinotecan-containing first-line regimens. This is in contrast to an evaluation of 86 patients in which pretreatment bilirubin level was strongly associated with the development of severe neutropenia[20,21,36]. In these studies, a majority of patients had been pretreated with other regimens, which may have affected their ability to metabolize SN-38, while in our investigation, all patients were chemotherapy-naive. Patients in the other reports received high-dose irinotecan monotherapy (300-350 mg/m2 every 3 weeks), whereas the present study evaluated combination therapies utilizing lower doses of irinotecan, including FOLFIRI, which has become a standard front-line treatment. However, both studies confirm that UGT1A1 testing has low sensitivity to predict severe neutropenia, as indicated by low R2[21,36]. This lack of predictive power limits the use of UGT1A1 genotyping in providing treatment guidance prior to initiating therapy.
###end p 51
###begin p 52
###xml 120 126 120 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
Currently, unidentified factors may significantly add to predictive accuracy for ANC nadir, arguing against reliance on UGT1A1 genotype alone, which has little predictive utility.
###end p 52
###begin p 53
###xml 208 212 208 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">[37]</xref>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">[1</xref>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
###xml 488 491 488 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40">40]</xref>
###xml 695 698 695 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">[41</xref>
###xml 699 702 699 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">42]</xref>
###xml 1228 1236 <span type="species:ncbi:9606">patients</span>
With the continuing introduction of newer and more effective agents, combination therapies introduce the possibility that one drug may influence the activity of an enzyme involved in the metabolism of another[37]. Apart from genetic factors affecting the complex metabolism of irinotecan, which involves multiple enzymatic and transportational processes enacted at various cellular locales and requires participation of the cytochrome p450 system, efflux pumps, and other mechanisms[1,38-40], over 29 genes are implicated in the integrated metabolism of 5-FU, a core component of the FOLFOX and FOLFIRI regimens. Genetic variation in any of these genes can affect clinical response or toxicities[41,42]. Additionally, the toxicities experienced in this study may have been at least partially a result of simultaneous exposure to the multiple drugs comprising the mIFL, CapeIRI, and FOLFIRI regimens, with or without the addition of celecoxib or thalidomide, rather than to irinotecan as a single component of these complex treatment protocols. A limitation of the current study is that we did not undertake pharmacokinetic analyses of SN-38 levels either prior to or following exposure to irinotecan; variations in levels among patients may have relevance to the likelihood of increased toxicity reactions. Diarrhea also was not included as an endpoint in our study and consequently is not included in the model.
###end p 53
###begin p 54
###xml 253 257 253 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">[41]</xref>
###xml 410 414 410 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43">[43]</xref>
###xml 624 628 624 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">[44]</xref>
###xml 816 820 816 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">[37]</xref>
###xml 1133 1136 1133 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">[41</xref>
###xml 1137 1140 1137 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">45]</xref>
###xml 373 380 <span type="species:ncbi:9606">patient</span>
###xml 487 494 <span type="species:ncbi:9606">patient</span>
The utility of pretreatment screening for a single nucleotide polymorphism prior to the administration of sophisticated regimens employing combinations of agents remains to be determined. Polymorphisms involved in drug metabolism do not act in isolation[41]; neither is the presence of a specific, single nucleotide polymorphism an unequivocal indicator that an individual patient will show an altered response[43]. Variability in drug actions reflect heritable changes in an individual patient's metabolism of the drug, its specific target, and the complex biologic milieu in which drugs and their target molecules interact[44]. Focus on single-gene polymorphisms, e.g., 6/6, 6/7, or 7/7, may be less useful than screening for interindividual variations in multiple processes that comprise a pharmacokinetic pathway[37]. Investigations geared toward comprehensive analysis of numerous metabolic and degradative genetic components, and delineation of the functional importance of genetic variants across a range of drug pathway genes, may represent a more useful approach to integrating pharmacogenetic testing in cancer chemotherapy[41,45].
###end p 54
###begin p 55
###xml 379 383 379 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46">[46]</xref>
###xml 508 511 508 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">[44</xref>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b47">47</xref>
###xml 515 518 515 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b48">48]</xref>
###xml 220 228 <span type="species:ncbi:9606">patients</span>
###xml 371 379 <span type="species:ncbi:9606">patients</span>
Focusing on comprehensive genetic profiles rather than on single specific polymorphisms offers the promise of enormous benefit from chemotherapy; recently, a genetic signature comprising 14 genes identified in tumors of patients with mCRC was predictive of response to FOLFIRI (100% specificity); however, this signature needs to be validated in an independent cohort of patients[46]. Technologic and computational obstacles remain before comprehensive genetic analysis is fully integrated into clinical care[44,47,48].
###end p 55
###begin p 56
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 145 151 145 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1</italic>
###xml 649 652 649 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">[37</xref>
###xml 653 656 653 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b49">49]</xref>
###xml 368 376 <span type="species:ncbi:9606">patients</span>
This study demonstrates that the ability of UGT1A1 to predict neutropenia is, at best, modest. Adding baseline bilirubin to the model containing UGT1A1 genotype does not substantially increase explanatory power. Determining the specific contribution to the development of toxicity of variations of genes involved in drug-metabolizing processes can be difficult, given patients' heterogeneous backgrounds and the complex physiologic changes that can be caused by multiple, confounding factors, including comorbid conditions, organ dysfunction secondary to previous treatments, tumor behavior, nutritional status, and effects of concurrent medications[37,49]. It is not surprising, therefore, that a single polymorphism may not contribute sufficient information for assessment of toxicity risk beyond that suggested by clinical indicators.
###end p 56
###begin p 57
Research support for this study was provided by Pfizer Inc. Editorial assistance for this manuscript was provided by Adelphi Inc. and funded by Pfizer Inc.
###end p 57
###begin title 58
Conflict of Interest
###end title 58
###begin p 59
All authors are employees of Pfizer.
###end p 59
###begin title 60
References
###end title 60
###begin article-title 61
Pharmacogenetic influences on treatment response and toxicity in colorectal cancer
###end article-title 61
###begin article-title 62
Therapy for metastatic colorectal cancer
###end article-title 62
###begin article-title 63
Critical evaluation of current treatments in metastatic colorectal cancer
###end article-title 63
###begin article-title 64
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study
###end article-title 64
###begin article-title 65
###xml 12 20 <span type="species:ncbi:9606">patients</span>
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
###end article-title 65
###begin article-title 66
Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer
###end article-title 66
###begin article-title 67
###xml 108 116 <span type="species:ncbi:9606">patients</span>
Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer
###end article-title 67
###begin article-title 68
###xml 108 116 <span type="species:ncbi:9606">patients</span>
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
###end article-title 68
###begin article-title 69
###xml 52 59 <span type="species:ncbi:9606">patient</span>
MAX2-A convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials
###end article-title 69
###begin article-title 70
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Predictors of tolerance to chemotherapy in older cancer patients: A prospective pilot study
###end article-title 70
###begin article-title 71
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials
###end article-title 71
###begin article-title 72
Tailoring chemotherapy in advanced colorectal cancer
###end article-title 72
###begin article-title 73
Pharmacogenetics and pharmacogenomics as new tools to optimise cancer chemotherapy
###end article-title 73
###begin article-title 74
###xml 97 105 <span type="species:ncbi:9606">patients</span>
The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
###end article-title 74
###begin article-title 75
###xml 188 193 <span type="species:ncbi:9606">human</span>
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
###end article-title 75
###begin article-title 76
###xml 116 121 <span type="species:ncbi:9606">human</span>
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism
###end article-title 76
###begin article-title 77
The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome
###end article-title 77
###begin article-title 78
Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome
###end article-title 78
###begin article-title 79
###xml 15 20 <span type="species:ncbi:9606">human</span>
Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene
###end article-title 79
###begin article-title 80
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
###end article-title 80
###begin article-title 81
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
###end article-title 81
###begin article-title 82
Pharmacogenetics of anticancer agents: Lessons from amonafide and irinotecan
###end article-title 82
###begin article-title 83
###xml 21 29 <span type="species:ncbi:9606">patients</span>
UGT1A1 genotyping in patients undergoing treatment with irinotecan
###end article-title 83
###begin article-title 84
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis
###end article-title 84
###begin article-title 85
Randomized controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study
###end article-title 85
###begin article-title 86
###xml 107 115 <span type="species:ncbi:9606">patients</span>
Multivariate predictive models of neutropenia associated with irinotecan treatment in previously untreated patients with colorectal cancer: A comparison of infusional and bolus regimens
###end article-title 86
###begin article-title 87
###xml 21 30 21 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT1A1*28</italic>
###xml 48 56 48 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UGT2B7*2</italic>
###xml 128 133 <span type="species:ncbi:9606">human</span>
Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes
###end article-title 87
###begin article-title 88
UGT1A1*28, toxicity and outcome in advanced colorectal cancer: Results from Trial N9741
###end article-title 88
###begin article-title 89
Irinotecan-induced neutropenia and UGT1A1*28: Does dose matter?
###end article-title 89
###begin article-title 90
Pharmacogenomics in colorectal cancer
###end article-title 90
###begin article-title 91
###xml 113 121 <span type="species:ncbi:9606">patients</span>
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients
###end article-title 91
###begin article-title 92
###xml 51 59 <span type="species:ncbi:9606">patients</span>
UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
###end article-title 92
###begin article-title 93
Uridine diphosphate glucoronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy
###end article-title 93
###begin article-title 94
###xml 83 91 <span type="species:ncbi:9606">patients</span>
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan
###end article-title 94
###begin article-title 95
###xml 41 49 <span type="species:ncbi:9606">patients</span>
UGT1A1 promoter genotype and toxicity in patients with advanced colorectal cancer treated with irinotecan-containing chemotherapy
###end article-title 95
###begin article-title 96
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity
###end article-title 96
###begin article-title 97
Modulation of cytochrome P450 activity: Implications for cancer therapy
###end article-title 97
###begin article-title 98
###xml 37 42 <span type="species:ncbi:9606">human</span>
Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions
###end article-title 98
###begin article-title 99
###xml 58 64 <span type="species:ncbi:9606">humans</span>
Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans
###end article-title 99
###begin article-title 100
###xml 99 107 <span type="species:ncbi:9606">patients</span>
Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients
###end article-title 100
###begin article-title 101
Cancer pharmacogenetics
###end article-title 101
###begin article-title 102
###xml 136 144 <span type="species:ncbi:9606">patients</span>
Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls
###end article-title 102
###begin article-title 103
Pharmacogenomics and individualized drug therapy
###end article-title 103
###begin article-title 104
Pharmacogenetics research network. Pharmacogenomics: Challenges and opportunities
###end article-title 104
###begin article-title 105
Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer
###end article-title 105
###begin article-title 106
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan
###end article-title 106
###begin article-title 107
Implications of pharmacogenomics for drug development and clinical practice
###end article-title 107
###begin article-title 108
Genomic medicine: Genetic variation and its impact on the future of health care
###end article-title 108
###begin article-title 109
TPMT
###end article-title 109
###begin article-title 110
UGT1A1 and DPYD: Genotyping to ensure safer cancer therapy?
###end article-title 110

